SPAC Biotech Acquisition defers shareholders meeting on Blade Therapeutics merger approval
seekingalpha.com
finance
2022-06-03 09:45:17

cagkansayin/iStock via Getty Images Biotech Acquisition (NASDAQ:BIOT) said a meeting of its shareholders to approve its proposed business combination with Blade Therapeutics has been postponed to a later date, which has not yet been determined. BIOT said the postponement of the extraordinary general meeting is aimed to allow for more time to satisfy all conditions necessary to effect the closing of the proposed Business Combination. The company added that as of June 2, a sufficient number of its shareholders have voted to approve the business combination.
